PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ--(Marketwire - February 19, 2013) - Agennix AG (FRANKFURT: AGX) today announced that the Company will publish its financial results for fiscal year 2012 on Thursday, March 28, 2013 followed by a conference call to discuss the results and to provide a business update.
The conference call, which will be conducted in English, will be also held on Thursday, March 28, 2013 at 9 AM ET/2 PM CET.
A live webcast will be available on the Agennix website at www.agennix.com. A replay will be available via the website following the live event.
Dial-in numbers for the call are as follows:
Participants from Europe:
0049 (0)69 710 445 598
0044 (0)20 3003 2666
Participants from the U.S.:
1 212 999 6659
Please dial in 10 minutes before the beginning of the call.
About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially lengthen and improve the lives of critically ill patients in areas of major unmet medical need. The Company’s clinical development programs include oral talactoferrin alfa; a topical gel form of talactoferrin and RGB-286638, a multi-targeted kinase inhibitor. Agennix’s registered seat is in Heidelberg, Germany. The Company has two sites of operation: Planegg/Munich, Germany and Princeton, New Jersey. For additional information, please visit the Agennix website at www.agennix.com.
This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. The achievement of positive results in early stage clinical studies does not ensure that later stage clinical studies will be successful. There can be no guarantee that the Company will have or be able to obtain the financial resources to conduct additional studies with its product candidates or that it will be successful in pursuing a strategic transaction. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Agennix® is a trademark of Agennix AG.
For further information, please contact:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com
In the U.S.:
Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com
